ALLO - Latest Allogene data drags down peers on safety concerns

Allogene Therapeutics (NASDAQ:ALLO) down nearly a third premarket after FDA placed clinical hold on its AlloCAR T trials yesterday. The Agency's decision was based after a chromosomal abnormality was reported in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study. Cellectis (NASDAQ:CLLS) plunges 14% premarket in sympathy with clinical data from ALLO. MaxCyte (NASDAQ:MXCT) falls 9% premarket at $9.76. MXCT recently made a U.S. debut in July by pricing IPO at $13. The company and Allogene have inked a licensing deal to develop allogeneic CAR T therapies using a MaxCyte's platform. Caribou Biosciences (NASDAQ:CRBU), a biotech developing genome-edited allogeneic cell therapies also dropped 3% premarket after Allogene's data. CRBU closed its IPO in July and is trading ~38% higher from its IPO price of $16.

For further details see:

Latest Allogene data drags down peers on safety concerns